patient receiving vaccine in arm

Kaiser Permanente has resumed use of the Johnson & Johnson COVID-19 vaccine, as availability requires, this is in response to the recommendation of the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and state public health authorities.

After CDC and FDA temporarily paused the use of the vaccine for rare instances of blood clotting. Kaiser Permanente’s infectious disease physicians along with other experts reviewed all available data and found that Johnson & Johnson COVID-19 vaccine’s known and potential benefits outweigh its known and potential risks.

Kaiser Permanente has followed and will continue to follow federal and state guidelines requiring women under the age of 50 to be informed about the increased risk of blood clots. As well as following other clinical guidance from the FDA and CDC to ensure the safe and effective use of the Johnson & Johnson COVID-19 vaccine.


FDA – Janssen COVID Vaccine

CDC – Janssen Vaccine